Interim data from this trial after 24 weeks of dosing recently reported mean dystrophin protein expression levels of 9% (muscle content-adjusted) and 5.5% (unadjusted), with mean exon skipping levels of 57% (Wave life sciences announces positive interim data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in boys with Duchenne muscular dystrophy amenable to exon 53 skipping - wave life sciences Available from: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-interim-data-forward-53). This evidence concerns the gene DMD and Duchenne muscular dystrophy.